Letrozol 1a Pharma

Letrozole, the active ingredient in Letrozol 1a Pharma, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of postmenopausal hormone receptor‑positive breast cancer, including adjuvant therapy for early‑stage disease, by lowering estrogen levels that fuel tumor growth.

GNH USA supplies Letrozol 1a Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Letrozole is used in hormone‑driven breast cancer pathways to reduce estrogen exposure.

- Postmenopausal hormone receptor‑positive breast cancer: reduces tumor progression by lowering circulating estrogen. - Adjuvant treatment of early‑stage breast cancer: decreases risk of disease recurrence after surgery. - Estrogen‑dependent breast cancer: provides endocrine therapy by inhibiting aromatase‑mediated estrogen synthesis.

Letrozole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aches in joints or muscles. - Fatigue: persistent tiredness. - Nausea: upset stomach and possible vomiting. - Headache: mild to moderate cranial pain. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Severe liver injury: elevated enzymes or hepatitis. - Bone fractures: increased risk of osteoporosis‑related breaks. - Pulmonary embolism: blood clot in lung vessels. - Allergic reaction: rash, swelling, or anaphylaxis. - Elevated cholesterol: significant rise in lipid levels. - QT interval prolongation: potential cardiac rhythm disturbance.

Before initiating letrozole therapy, several safety considerations should be reviewed.

- Assess bone health: monitor bone mineral density and consider calcium/vitamin D supplementation. - Evaluate liver function: perform baseline hepatic tests and repeat as needed. - Review cardiovascular risk: consider history of thrombosis or hyperlipidaemia. - Avoid use in pregnancy: contraindicated due to teratogenic risk (Category X). - Counsel on hot flashes: advise patients about possible vasomotor symptoms. - Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Letrozole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce letrozole plasma levels. - Estrogen‑containing therapies (hormone replacement, oral contraceptives): counteract aromatase inhibition. - Warfarin: may increase anticoagulant effect and INR.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (e.g., fluoxetine): possible modest effect on metabolism. - Antihypertensive agents: monitor blood pressure as hormonal changes may alter response. - Lipid‑lowering drugs (statins): observe for any changes in lipid profile.